Gedeon Richter Plc. ("Richter") today announced that it has entered into a license and distribution agreement with L.D. Collins & Co. Limited
("L.D. Collins"), a UK based company, to commercialize its 400mg progesterone containing assisted reproduction technology (ART) product, Cyclogest® in 27 EU countries. Marketing authorizations have already been granted in the above territory. Following the transfer of the marketing authorization holder to Richter, the launch of the product is expected to be executed from early 2019.